Ask AI
Myasthenia Gravis Targeted Treatment

CE / CME

Mechanism Matters: The Future of Targeted Treatments in Myasthenia Gravis

Nurse Practitioners/Nurses: 0.50 Nursing contact hour, including 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: May 26, 2026

Expiration: May 25, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96:114-122.
  2. San PP, Jacob S. Role of complement in myasthenia gravis. Front Neurol. 2023;14:1277596.
  3. Wolfe GI, Ward ES, de Haard H, et al. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. J Neurol Sci. 2021;430:118074.
  4. Bhandari V, Bril V. FcRn receptor antagonists in the management of myasthenia gravis. Front Neurol. 2023;14:1229112.
  5. Eculizumab [prescribing information]. Boston, MA: Alexion Pharmaceuticals; 2025.
  6. Ravulizumab-cwvz [prescribing information]. Boston, MA: Alexion Pharmaceuticals; 2024.
  7. Zilucoplan [prescribing information]. Smyrna, GA: UCB Inc; 2026.
  8. Efgartigimod alfa-fcab [prescribing information]. Wilmington, DE: Argenx US Inc; 2025.
  9. Rozanolixizumab-noli [prescribing information]. Smyrna, GA: UCB Inc; 2025.
  10. Nipocalimab-aahu [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2025.
  11. Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412:113-128.
  12. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-725.
  13. Huntemann N, Gerischer L, Herdick M, et al. C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2025;96:310-321.
  14. Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20:526-536.
  15. Antozzi C, Meisel A, Howard JF Jr, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24:105-115.
  16. Di Martino G, Rini N, Bonaventura A, et al. Complement inhibitors in generalized myasthenia gravis: comparison of administration schedules, efficacy, and safety. J Clin Med. 2025;14:8205.
  17. Vu T, Habib A, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407:1712-1724.
  18. Gwathmey KG, Sacca F, Howard JF Jr, et al. Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis: primary results from the phase three, randomized, double-blind, placebo-controlled PREVAIL study. Presented at: American Academy of Neurology Annual Meeting; April 18-22, 2026. Abstract S14-006.
  19. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22:383-394.
  20. Yan C, Yue Y, Guan Y, et al. Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol. 2024;81:336-345.
  21. Efgartigimod alfa and hyaluronidase-qvfc [prescribing information]. Wilmington, DE: Argenx US Inc; 2025.
  22. Jacob S, Hashim M, Hutton B, et al. Indirect comparison of nipocalimab versus efgartigimod and rozanolixizumab in the treatment of generalized myasthenia gravis. Adv Ther. 2026;43:2125-2138.
  23. Filippakopoulou E, Gavriilaki M, Arnaoutoglou M, et al. Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis. J Neurol. 2026;273:244.
  24. Meisel A, Annane D, Vu T, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1:EVIDoa2100066.
  25. Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22:395-406.
  26. Jindal S, Pedersen DV, Gera N, et al. Characterization of the bispecific VHH antibody gefurulimab targeting complement component 5, and designed for low volume subcutaneous administration. Mol Immunol. 2024;165:29-41.
  27. Benatar M, Wiendl H, Nowak R, Zheng Y, Macias W. Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial. BMJ Neurol Open. 2024;6:e000536.